Dr Ed Wilson
Dr Ed Wilson is pleased to consider applications from prospective PhD students.
Decision analysis, economic evaluation/cost-effectiveness, efficient research design.
Symplectic Elements feed provided by Research Information, University of Cambridge
Wilson E, Mugford M, Barton G, Shepstone L. Efficient Research Design: using Value of Information Analysis to estimate the optimal mix of top-down and bottom-up costing approaches in an economic evaluation alongside a clinical trial. Medical Decision Making [In Press] Tao L, Wilson E, Wareham N, Sandbaek A, Rutten G, Lauritzen T, Khunti K, Davies M, Borch-Johnsen K, Griffin S, Simmons R. Cost-effectiveness of early intensive multifactorial treatment for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster randomised controlled trial. Diabetic Medicine 2015;32(7):907-19. DoI: 10.1111/dme.12711 Wilson E. A practical guide to value of information analysis. Pharmacoeconomics 2015;33:105-21 Wilson E. on behalf of the Cochrane Agenda & Priority Setting Methods Group and Campbell & Cochrane Economics Methods Group. Which study when? Proof of concept of a proposed automated tool to help Cochrane review groups decide which reviews to update first. Cochrane Methods. Cochrane DB Syst Rev 2014 Suppl1:29-31 Shemilt I, Wilson E, Vale L. Quality Assessment in Modeling in Decision Analytic Models for Economic Evaluation. In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 3. San Diego: Elsevier 2014. pp 218-223 Wilson E, Shulgina L, Cahn A, Chilvers E, Parfrey H, Clark A, Twentyman O, Wilson A. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 2014;32:87-99. Tao L, Wilson E, Griffin S, Simmons R. Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort. Value in Health 2013;16(6):1074-80 Wilson E, Emery J, Kinmonth A, Prevost A, Morris H, Humphrys E, Hall P, Burrows N, Bradshaw L, Walls J, Norris P, Johnson M, Walter F. The cost-effectiveness of a novel diagnostic aid (the MoleMateTM system) for the management of pigmented skin lesions in primary care: a decision analytic model. Value in Health 2013;16(2):356-66 Walter F, Morris H, Humphrys E, Hall P, Prevost A, Kinmonth A, Burrows N, Bradshaw L, Wilson E, Norris P, Walls J, Johnson M, Emery J. Management of suspicious pigmented lesions in primary care: randomised controlled trial of adding a SIAscopic diagnostic aid to best practice. British Medical Journal 2012;345:e4110 Gurusamy K, Wilson E, Burroughs AK, Davidson BR. Cost-utility and value-of-information analysis of intra-operative versus pre-operative endoscopic sphincterotomy in patients with gallbladder and common bile duct stones. Applied Health Economics and Health Policy 2012;10(1):15-29 Price D, Musgrave S, Shepstone L, Hillyer E, Sims E, Gilbert R, Juniper E, Ayres J, Kemp L, Blyth A, Wilson E, Wolfe S, Freeman D, Mugford M, Murdoch J, Harvey I. Leukotriene antagonists as first-line or add-on asthma controller therapy. New England Journal of Medicine 2011;364(18):1695-707 Price D, Musgrave S, Wilson E, Sims E, Shepstone L, Blyth A, Murdoch J, Mugford M, Juniper E, Ayres J, Wolfe S, Freeman D, Lipp A, Gilbert R, Harvey I. A pragmatic single-blind RCT and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps two and three of the national asthma guidelines. Health Technology Assessment 2011;15(21):1-132 Wilson E, The cost-effectiveness of imiquimod 5% cream compared with methyl aminolaevulinic acid based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 2010;28(11):1055-64 Wilson E, Sims E, Musgrave S, Shepstone L, Blyth A, Murdoch J, Mugford M, Juniper E, Ayres J, Wolfe S, Freeman D, Gilbert R, Harvey I, Hillyer E, Price D. The cost-effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. Pharmacoeconomics 2010;28(7):585-95 Wilson E, Price D, Musgrave S, Sims E, Shepstone L, Murdoch J, Mugford M, Blyth A, Juniper E, Ayres J, Wolfe S, Freeman D, Gilbert R, Hillyer R, Harvey I. The cost-effectiveness of leukotriene receptor antagonists versus long acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. Pharmacoeconomics 2010;28(7):597-608 Wilson E, Abrams K. From evidence-based economics to economics based evidence: using systematic review to inform the design of future research in Shemilt I, Donaldson C, Mugford M, et al. (eds) Evidence Based Decisions and Economics: health care, social welfare, education and criminal justice. Wiley 2010 Wilson E, Ford G, Robinson T, Mistri A, Jagger C, Potter J. Controlling hypertension immediately post stroke - a cost utility analysis of a pilot randomised controlled trial. Cost Effectiveness and Resource Allocation 2010;8:3 Wilson E, Gurusamy K, Gluud C, Davidson B. A cost-utility and value of information analysis of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. British Journal of Surgery 2010;97:210-9. Gurusamy K, Samraj K, Wilson E, Davidson B. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis ? a meta-analysis of randomised clinical trials. British Journal of Surgery 2010;97:141-50. Wilson E, Thalanany M, Shepstone L, Charlesworth G, Poland F, Harvey I, Price D, Reynolds S, Mugford M. Befriending carers of people with dementia: a cost utility analysis. International Journal of Geriatric Psychiatry 2009;24:610-23. Charlesworth G, Shepstone L, Wilson E, Reynolds S, Mugford M, Price D, Harvey I, Poland F. Befriending carers of people with dementia: a randomised controlled trial. British Medical Journal 2008;386:1284-7. doi:10.1136/bmj.39549.548831.AE Charlesworth G, Mugford M, Shepstone L, Wilson E, Thalanany M, Poland F. Does befriending by trained lay workers improve psychological well-being and quality of life for carers of people with dementia (PwD), and at what cost?: a randomised controlled trial. Health Technology Assessment 2008; 12(4). Wilson E, Jayne D, Dellow E, Fordham R. The Cost-Effectiveness of Mycophenolate Mofetil (MMF) as First Line Therapy in Active Lupus Nephritis. Rheumatology 2007; 46:1096-1101. Doi:10.1093/rheumatology/kem054 Wilson E, Sussex J, Macleod C, Fordham R. Prioritizing Health Technologies in a Primary Care Trust. Journal of Health Services Research and Policy 2007; 12(2):80-85 Pacini M, Smith R, Wilson E, Holland R. Home-based medication review in older people: is it cost-effective? Pharmacoeconomics 2007;25(2):171-80 Heller R, Gemmell I, Wilson E, Fordham R, Smith R. Using economic analyses for local priority setting: the population cost-impact approach. Applied Health Economics and Health Policy 2006; 5(1):45-54 Wilson ECF, Rees J, Fordham R. Developing a prioritisation framework in an English Primary Care Trust. Cost Effectiveness and Resource Allocation 2006;4:3 Ledger, WL, Anumba D, Marlow N, Thomas CM, Wilson ECF. The costs to the NHS of multiple births after IVF treatment in the UK. British Journal of Obstetrics & Gynaecology 2006;113 (1): 21-25. doi: 10.1111/j.1471-0528.2005.00790.x Wilson E, McKeen E, Scuffham P, Brown M, Wylie K, Hackett G. The cost to the United Kingdom National Health Service of Managing Erectile Dysfunction. Pharmacoeconomics 2002; 20(13): 879-889 Scuffham P, Legood R, Wilson E, Kennedy-Martin T. The incidence and cost of injurious falls associated with visual impairment in the UK. Visual Impairment Research 2002;4(1):1-14